<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916899</url>
  </required_header>
  <id_info>
    <org_study_id>DoTBal_FVI_001</org_study_id>
    <nct_id>NCT04916899</nct_id>
  </id_info>
  <brief_title>Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program</brief_title>
  <official_title>Study to Evaluate the Safety of the Use of doTBal (Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV, observational, cohort, prospective study. With duration according to the indicated&#xD;
      scheme, 6 months of treatment (2 intensive months and 4 months of sotén) for pulmonary&#xD;
      tuberculosis. Follow-up with patients will continue for a month after completion of the&#xD;
      indicated scheme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study was to detect and analyze the adverse events presented during the&#xD;
      administration of the drug doTBal® in patients of the Health Centers of the Ministry of&#xD;
      Health of the municipalities of Colima, Tecomán and Manzanillo, of the State of Colima. All&#xD;
      patients detected in the selected centers that are indicated treatment with doTBal® under the&#xD;
      TAES (Strictly Supervised Shortened Treatment) regimen or who are already on this drug&#xD;
      (according to their clinical record), will be asked to participate in the study explaining to&#xD;
      them the same and requesting their informed consent in writing. In the case of minors, they&#xD;
      will also be asked to provide their informed assent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To detect adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>To detect the adverse events presented during the administration of the drug doTBal®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of occurrence of adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>Determine the frequency of appearance of each adverse event detected with the administration of the drug doTBal®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of each of the adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>Determine the severity of each of the adverse events during the administration of the drug doTBal®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Causality of each of the adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>Analyze the causality of each of the adverse events detected during the administration of the drug doTBal® (using the Tree-orange algorithm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparatus and systems affected with adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>Analyze the apparatus and systems affected with adverse events during drug administration of doTBal®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Factors associated with the presentation of adverse events</measure>
    <time_frame>23 months</time_frame>
    <description>Analyze other factors associated with the presentation of adverse events during doTBal® administration, such as age, sex, pregnancy, etc.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">47</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol</arm_group_label>
    <description>Pharmaceutical Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Administration way: oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol</intervention_name>
    <description>Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral</description>
    <arm_group_label>Group A: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol</arm_group_label>
    <other_name>doTbal®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 12 years old, who are being trated with doTBal® under strictly supervised&#xD;
        shorter treatment regimen and sign informes consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders with a diagnosis of active pulmonary tuberculosis.&#xD;
&#xD;
          -  Over 12 years old.&#xD;
&#xD;
          -  Patients who are being treated with doTBal® under the TAES (Strictly Supervised&#xD;
             Shorter Treatment) regimen.&#xD;
&#xD;
          -  Informed consent (and in the case of minors informed consent) signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Withdrawal of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Maldonado Hernández, MS.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Colima</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Castrejón, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Tecomán</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José G Maya Campos, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Avanzado de Atención Primaria a la Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adara M Cárdenas Sánchez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Salud Urbano Salangua</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratorio Silanes, S.A. de C.V.</name>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.dof.gob.mx/nota_detalle.php?codigo=5601541&amp;fecha=30/09/2020</url>
    <description>NOM-220-SSA1-2016: 2.1.11</description>
  </link>
  <link>
    <url>https://www3.paho.org/hq/index.php?option=com_docman&amp;view=download&amp;category_slug=documentos-8499&amp;alias=33513-buenas-pra-cticas-farmacovigilancia-ame-ricas-2010-513&amp;Itemid=270&amp;lang=es</url>
    <description>Buenas Prácticas de Farmacovigilancia para las Américas, 2008</description>
  </link>
  <link>
    <url>http://dof.gob.mx/nota_detalle.php?codigo=5321934&amp;fecha=13/11/2013</url>
    <description>NORMA Oficial Mexicana NOM-006-SSA2-2013, Para la prevención y control de la tuberculosis.</description>
  </link>
  <reference>
    <citation>Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62.</citation>
    <PMID>12588714</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>Tuberculosis treatment</keyword>
  <keyword>adverse events</keyword>
  <keyword>pharmacovigilance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

